PL2097064T3 - Terapia anaplerotyczna choroby Huntingtona i innych chorób poliglutaminowych - Google Patents

Terapia anaplerotyczna choroby Huntingtona i innych chorób poliglutaminowych

Info

Publication number
PL2097064T3
PL2097064T3 PL07847692T PL07847692T PL2097064T3 PL 2097064 T3 PL2097064 T3 PL 2097064T3 PL 07847692 T PL07847692 T PL 07847692T PL 07847692 T PL07847692 T PL 07847692T PL 2097064 T3 PL2097064 T3 PL 2097064T3
Authority
PL
Poland
Prior art keywords
huntington disease
polyglutamine diseases
anaplerotic therapy
anaplerotic
therapy
Prior art date
Application number
PL07847692T
Other languages
English (en)
Inventor
Alexandra Dürr
Fanny Mochel
Original Assignee
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Nat Sante Rech Med filed Critical Inst Nat Sante Rech Med
Publication of PL2097064T3 publication Critical patent/PL2097064T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/03—Organic compounds
    • A23L29/035—Organic compounds containing oxygen as heteroatom
    • A23L29/04—Fatty acids or derivatives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL07847692T 2006-12-04 2007-12-03 Terapia anaplerotyczna choroby Huntingtona i innych chorób poliglutaminowych PL2097064T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06291873A EP1929995A1 (en) 2006-12-04 2006-12-04 Anaplerotic therapy of Huntington disease and other polyglutamine diseases
PCT/EP2007/063181 WO2008068230A1 (en) 2006-12-04 2007-12-03 Anaplerotic therapy of huntington disease and other polyglutamine diseases
EP07847692.6A EP2097064B1 (en) 2006-12-04 2007-12-03 Anaplerotic therapy of huntington disease and other polyglutamine diseases

Publications (1)

Publication Number Publication Date
PL2097064T3 true PL2097064T3 (pl) 2016-02-29

Family

ID=37733780

Family Applications (1)

Application Number Title Priority Date Filing Date
PL07847692T PL2097064T3 (pl) 2006-12-04 2007-12-03 Terapia anaplerotyczna choroby Huntingtona i innych chorób poliglutaminowych

Country Status (11)

Country Link
US (5) US20100063147A1 (pl)
EP (3) EP1929995A1 (pl)
CY (1) CY1116938T1 (pl)
DK (1) DK2097064T3 (pl)
ES (2) ES2552843T3 (pl)
HK (1) HK1223829A1 (pl)
HU (1) HUE026217T2 (pl)
PL (1) PL2097064T3 (pl)
PT (1) PT2097064E (pl)
SI (1) SI2097064T1 (pl)
WO (1) WO2008068230A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
JP5765839B2 (ja) * 2009-12-05 2015-08-19 国立大学法人名古屋大学 球脊髄性筋萎縮症治療薬
EP2519234B1 (en) * 2009-12-30 2017-06-28 Baylor Research Institute Anaplerotic therapy for alzheimer's disease
MX2012014520A (es) * 2010-06-14 2013-03-05 Baylor Res Inst Dieta de triheptanoina para tratamiento de enfermedad del cuerpo de poliglucosano (apbd).
BR112015013349A2 (pt) * 2012-12-13 2017-07-11 Baylor Res Institute At Dallas trieptanoína para o tratamento de deficiência de transportador de glicose 1
AU2014348457B2 (en) * 2013-11-14 2019-04-18 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof
WO2016004375A2 (en) * 2014-07-02 2016-01-07 Ridge Diagnostics, Inc. Methods and materials for treating pain and depression
AU2017277005B2 (en) 2016-06-08 2022-12-22 Sunregen Healthcare Ag Lipids with odd number of carbon atoms and their use as pharmaceutical composition or nutritional supplement

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4025649A (en) 1974-08-19 1977-05-24 Labaz Acetic acid derivatives having pharmacological activity and compositions containing the same
DE3032300A1 (de) 1980-08-27 1982-04-01 Alfred Ing. Wien Lohninger Mittel zur parenteralen ernaehrung
GB2104079B (en) 1981-08-14 1985-08-21 London Polytech New aminoacid isomers, their production and their medicinal use
US4753963A (en) 1985-09-26 1988-06-28 The Procter & Gamble Company Nutritional fat suitable for enteral and parenteral products
JP3486778B2 (ja) 1993-04-02 2004-01-13 三菱ウェルファーマ株式会社 アルツハイマー病予防治療剤
US20090253781A1 (en) 2002-05-24 2009-10-08 Btg International Limited Therapeutic compositions
US6740679B1 (en) * 1999-02-05 2004-05-25 Baylor University Medical Center Nutritional supplement or pharmaceutical preparation comprising triglycerides with seven-carbon fatty acid
JP4902906B2 (ja) * 1999-02-05 2012-03-21 ベイラー リサーチ インスティテュート 炭素数が７である脂肪酸を含むトリグリセリドを含有する栄養補助剤または医薬調製物
CA2389623A1 (en) 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US6835750B1 (en) * 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ES2323940T3 (es) 2000-05-01 2009-07-28 Accera, Inc. Uso de trigliceridos de cadena media para el tratamiento y prevencion de la enfermedad de alzheimer.
US20060189545A1 (en) * 2003-03-06 2006-08-24 Henderson Samuel T Novel chemical entities and methods for their use in treatment of metabolic disorders
US8399515B2 (en) 2003-05-20 2013-03-19 Baylor Research Institute Five and fifteen carbon fatty acids for treating metabolic disorders and as nutritional supplements
MX2007000304A (es) 2004-07-02 2007-06-15 Baylor Res Inst Metodo de tratamiento de enfermedad de almacenamiento de glucogeno o polisacaridos.
WO2006037069A1 (en) 2004-09-28 2006-04-06 Allergan, Inc. Compositions comprising nb-dnj, ne-dnj or d-glucaro-delta-lactam and their uses for the treatment of pain and other neurological conditions
KR20090003148A (ko) 2006-04-03 2009-01-09 액세라인크 나이와 관련된 기억 손상의 치료를 위한 케톤 생성조성물의 용도
KR20150038525A (ko) 2006-09-26 2015-04-08 베일러 리서치 인스티튜트 영양물 센서
EP1929995A1 (en) 2006-12-04 2008-06-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Anaplerotic therapy of Huntington disease and other polyglutamine diseases
PT2650380E (pt) 2007-07-31 2016-01-14 Accera Inc Utilização de testagem genómica e compostos cetogénicos para o tratamento de função cognitiva reduzida
WO2009124250A1 (en) 2008-04-03 2009-10-08 The Trustees Of The University Of Pennsylvania Compositions and methods for detecting tricarboxylic acid (tca) metabolic flux
EP2519234B1 (en) 2009-12-30 2017-06-28 Baylor Research Institute Anaplerotic therapy for alzheimer's disease
US20110301238A1 (en) 2010-06-02 2011-12-08 Borges Karin Seizure related disorders and therapeutic methods thereof
MX2012014520A (es) 2010-06-14 2013-03-05 Baylor Res Inst Dieta de triheptanoina para tratamiento de enfermedad del cuerpo de poliglucosano (apbd).
US9872850B2 (en) 2010-12-23 2018-01-23 Amazentis Sa Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
BR112015013349A2 (pt) 2012-12-13 2017-07-11 Baylor Res Institute At Dallas trieptanoína para o tratamento de deficiência de transportador de glicose 1
AU2014348457B2 (en) 2013-11-14 2019-04-18 The University Of Queensland Neurodegenerative disorders and methods of treatment and diagnosis thereof

Also Published As

Publication number Publication date
DK2097064T3 (en) 2015-11-23
WO2008068230A1 (en) 2008-06-12
ES2778525T3 (es) 2020-08-10
EP1929995A1 (en) 2008-06-11
US9717705B2 (en) 2017-08-01
EP3009135A1 (en) 2016-04-20
US20180021287A1 (en) 2018-01-25
US20100063147A1 (en) 2010-03-11
HK1223829A1 (zh) 2017-08-11
US20140364498A1 (en) 2014-12-11
EP2097064B1 (en) 2015-08-19
CY1116938T1 (el) 2017-04-05
HUE026217T2 (en) 2016-05-30
US20190365695A1 (en) 2019-12-05
EP2097064A1 (en) 2009-09-09
US20120165405A1 (en) 2012-06-28
EP3009135B1 (en) 2020-02-05
US10220014B2 (en) 2019-03-05
PT2097064E (pt) 2015-11-25
ES2552843T3 (es) 2015-12-02
SI2097064T1 (sl) 2016-01-29

Similar Documents

Publication Publication Date Title
EP2182983A4 (en) TREATMENT OF AMYLOIDOGENIC DISEASES
PT2097064E (pt) Terapia anaplerótica de doença de huntington e de outras doenças de poliglutamina
EP1968607A4 (en) TREATMENT OF CANCER AND OTHER DISEASES
SI2056863T1 (sl) Zdravljenje očesnih bolezni
BRPI0720046A2 (pt) Composição de suplemento nutricional para tratamento de doenças oculares
HK1131047A1 (en) Treatment of inflammatory diseases
HK1201046A1 (en) Methods of treating ophthalmic diseases
SI2056842T1 (sl) Modificiran galaktosil-ceramid za zdravljenje kancerogenih obolenj
EP1962839A4 (en) ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
EP2004204A4 (en) TREATMENT OF NEURODEGENERATIVE DISEASES
EP2160100B8 (en) Treatment of graft-versus-host disease
HK1148684A1 (en) Treatment of prion protein related diseases
ZA200806808B (en) Treatment of stressed patients
EP1962869A4 (en) TREATMENT OF RESPIRATORY DISEASES
EP2026822A4 (en) TOPICAL TREATMENT FOR EYE SURGERY DISEASES
GB0610183D0 (en) Treatment of neurodegenerative diseases
EP2001488A4 (en) PREVENTION AND TREATMENT OF CANCER AND OTHER DISEASES
EP2056858A4 (en) TREATMENT OF PULMONARY DISEASE CONDITIONS
EP2049899A4 (en) METHOD FOR THE PREVENTION AND TREATMENT OF DISEASES
GB2458868A8 (en) Treatment of protein aggregation diseases
BRPI0821539A2 (pt) composição para a prevenção e o tratamento de doenças metabólicas compreendendo o extrato de lysimachiae foenum-graeci herma
EP2025342A4 (en) THERAPEUTIC AGENT OR DEVELOPMENT INHIBITOR OF POLYGLUTAMINE DISEASE
EP1846013A4 (en) TREATMENT OF SKIN DISEASES
EP2059238A4 (en) THERAPEUTIC COMPOUNDS FOR DISEASES AND DISORDERS
GB0623740D0 (en) Treatment of disease